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Abstract: Lamotrigine (LTG), an antiepileptic drug, has been shown to be able to improve 
cerebral ischemic damage by limiting the presynaptic release of glutamate. The present study 
investigated further the neuroprotective effect of LTG on hypoxic-ischemic brain damage 
(HIBD) in neonatal rats and its relations to administration time and doses. The HIBD model 
was produced in 7-days old SD rats by left common carotid artery ligation followed by 2 h 
hypoxic exposure (8% oxygen). LTG was administered intraperitoneally with the doses of 5, 
10, 20, and 40 mg/kg 3 h after operation and the dose of 20 mg/kg 1 h before and 3 h, 6 h after 
operation. Blood and brain were sampled 24 h after operation. Nissl staining, terminal deoxy-
nucleotidyl transferase biotin-dUTP nick end labeling (TUNEL), and neuron-speciﬁ  c enolase 
(NSE) immunohistochemical staining were used for morphological studies. Water content in 
left cortex and NSE concentration in serum were determined. LTG signiﬁ  cantly reduced water 
content in the cerebral cortex, as well as the number of TUNEL staining neurons in the dentate 
gyrus and cortex in hypoxic-ischemia (HI) model. Furthermore, LTG signiﬁ  cantly decreased 
the NSE level in serum and increased the number of NSE staining neurons in the cortex. These 
effects, except that on water content, were dose-dependent and were more remarkable in the 
pre-treated group than in the post-treated groups. These results demonstrate that LTG may 
have a neuroprotective effect on acute HIBD in neonates. The effect is more prominent when 
administrated with higher doses and before HI.
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Introduction
Hypoxic ischemia (HI) is a common cause of brain damage in fetus and neonates. It is 
believed that HI may cause brain damages by activating a cascade of biochemical events, 
in which glutamate receptor plays an important role in triggering the toxic events (Hattori 
and Wasterlain 1990; Strijbos et al 1996). Previous studies have shown that the antago-
nists of N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methylisoxazole-
4-propionic acid (AMPA) receptor have a neuroprotective effect on hypoxic-ischemic 
brain damage (HIBD) in stroke models (Nellgard and Wieloch 1992; Scatton et al 1994). 
However, the adverse proﬁ  le of glutamate receptor antagonists limits their application 
in clinical practice (Scatton et al 1994). An alternative approach to ameliorate ischemic 
damage is to inhibit the presynaptic release of glutamate. Lamotrigine (LTG), a new 
kind of anticonvulsant drug with a action of inhibiting excessive presynaptic release of 
glutamate (Leach et al 1986) by blocking voltage-sensitive sodium channels (Cheung 
et al 1992; Lees and Leach 1993), has been demonstrated to be effective for HIBD in 
focal and global cerebral ischemia model (Graham et al 1993; Smith and Meldumr 1995; 
Wiard et al 1995; Crumrine et al 1997), as well as in the in vitro experiments (Calabresi 
et al 2003). Although the neuroprotective effects of LTG have been well demonstrated Biologics: Targets & Therapy 2008:2(2) 340
Yi et al
in ischemic models with adult rats and LTG has even been 
used as combination therapy for the patients with ischemic 
stroke (Chen et al 2002), little is known about its effects on 
neonatal HIBD (Papazisis et al 2007). Since the immature 
brain is highly sensitive to glutamate excitotoxicity (Barks 
and Silverstein 1992; Scatton et al 1994; Puka-Sundvall et al 
1997), it is conceivable that LTG might be useful for HIBD in 
neonates. Recent reports have shown that LTG has the ability 
of extensive placental transfer and also a good tolerability in 
infants (Ohman et al 2000; Mikati et al 2002), provided a basis 
for the clinical application in neonates or infants. The aim of 
the present study is to investigate the possible neuroprotective 
effects of LTG on HIBD in the perinatal period, and the 
relationships between the effect and administration time and 
doses. HI was induced according to the protocol in a widely 
used animal model of perinatal asphyxia (Rice and Vannucci 
1981). Histological and biochemical changes were examined 
to evaluate the damage of HI. Neuron-speciﬁ  c enolase (NSE), 
an isoenzyme of the glycolytic enzyme enolase (2-phospho-
D-glycerate hydrolase), was adopted as one of important quan-
titative index in our study, because it was reported that NSE 
is released into the cerebral spinal ﬂ  uid (CSF) and systemic 
circulation when neuronal damage has occurred (Schoerkhuber 
et al 1990; Martens et al 1998; Wang et al 1999; Verdu et al 
2001), and NSE is highly speciﬁ  c to the neuron.
Material and methods
HIBD model
All experiments were performed in accordance with the 
institutional animal care guidelines. Common carotid artery 
occlusion combined with hypoxia in postnatal day 7 (P7) rat 
pups was performed to induce HIBD (Rice and Vannucci 
1981). Rat pups were placed in an incubator with ambient 
temperature of 37 °C. Under deep ether anesthesia, the left 
common carotid artery was isolated, double ligated, and cut 
between the ligatures. After the surgical procedure, the ani-
mal was put to recover for 2 h in the temperature-controlled 
incubator and was then exposed to hypoxia for 2 h: placed in 
an enclosed and vented chamber that was partially submerged 
in water (37 °C). Hypoxia was induced by continuous ﬂ  ow of 
warmed, humidiﬁ  ed gas with 8% oxygen that was balanced 
with 92% nitrogen at the ﬂ  ow rate of 0.5 L/ml. All HI animals 
showed symptoms of hemiplegia and anoxia.
Study design
In order to evaluate the effects of different doses, P7 rats were 
divided into 4 different dose groups, ie, 5, 10, 20, and 40 mg/kg 
(n = 14 for each dose group). LTG was given intraperitoneally 
at 3 h after the ischemia. The dose of 20 mg/kg was selected 
to determine the therapeutic time window, which was 
administrated intraperitoneally 1 h before (pre-treated), or 
3 h, 6 h after the ischemia (post-treated) (n = 14 for each time 
point group). The dose range was derived from the previous 
report (Smith and Meldumr 1995; Wiard et al 1995; Lee 
et al 2000) and from our preliminary experiments. Since a 
pharmacokinetic study in rats has shown that LTG was rapidly 
absorbed following the intraperitoneal injection with a peak 
concentration achieved at 0.2–1.0 h for 20 mg/kg (Walker 
et al 2000), LTG was administered 1 h before ischemia to 
achieve a stable plasma concentration in the pre-treated group. 
It has been reported that LTG plasma elimination half-life is 
approximately 28 h in Wistar rat with 10 mg/kg intraperitoneally 
(Castel-Branco et al 2005), so a single dose administration 
was adopted in our study. Pure LTG (Glaxo Wellcome Co.) 
was suspended in 0.5% methylcellulose (1 mg/ml) before the 
experiment. Sham-operated controls (sham group, n = 14) and 
hypoxic-ischemic controls (HI group, n = 14) were only given 
equal volume of methylcellulose 3 h after HI. Six of 14 rats 
in each group were used for neuropathological examination, 
including immunohistochemical staining of NSE, terminal 
deoxynucleotidyl transferase biotin-dUTP nick end labeling 
(TUNEL) and Nissl staining. And 8 from each treatment 
group were used for determination of water content and serum 
NSE level.
Measurement of water content
A rat was anesthetized with chloral hydrate (350 mg/kg) 
24 h after HI, and the brain was rapidly excised. The sample 
of cortex from left cerebral hemisphere (ipsilateral to common 
carotid artery ligation) was weighed in milligram unit. The 
specimen was subsequently desiccated at 110 °C for 24 h. 
Reweighing the dry weight of the tissue, the water content 
was obtained by subtraction from the wet weight [water 
content = (wet weight- dry weight)/ wet weight × 100%].
Determination of neuron-speciﬁ  c 
enolase (NSE) in serum
Blood was collected during excision. Blood samples were left 
to clot at room temperature for 20–30 min and then centri-
fuged and frozen at −18 °C until assayed. The concentration 
of NSE in serum was measured by enzyme immunoassay 
NSE kit (Canag diagnostics AB Company, Denmark).
Neuropathology 
24 h after HI, the rat was anesthetized with 10% chloral 
hydrate (0.35 ml/100g, ip) and perfused transcardially Biologics: Targets & Therapy 2008:2(2) 341
Neuroprotection of LTG on HIBD in neonatal rats
with 10–15 ml of saline (0.9% NaCl), followed by 
20–30 ml of 4% paraformaldehyde in 0.01M PBS (pH 7.4). 
The brain was excised and postﬁ  xed for 24 h at 4 °C, then 
through 10%, 20%, and 30% sucroses for cytoprotection. 
OCT-embedded tissue was frozen at –80 °C and sectioned on 
a cryotome at a thickness of 30 μm along the coronal plane. 
The sections from B-2.2 to B-4.2 were selected. The adjacent 
sections were processed for either immunohistochemical 
staining of NSE or TUNEL and Nissl staining. NSE staining 
neurons in cortex and TUNEL positive cells in the cortex and 
dentate gyrus were quantiﬁ  ed by a single observer who had 
no knowledge of the treatment received by the animals using 
a light microscope (400×). The mean was derived from six 
counts (three sections from each sample and two areas from 
each section) in each animal for statistical analysis.
Statistical analysis
Data are expressed as mean ± SE. Data were analysed using 
the ANOVA test followed by post-hoc multiple comparisons 
by Dunnett’s test.
Results
The effect of LTG on brain edema
Hypoxic ischemia resulted in a signiﬁ  cant increase of the water 
content. The treatments of LTG 10 mg/kg reduced water 
contents in HI animals signiﬁ  cantly (P   0.01). No signiﬁ  cant 
difference in water content was detected between the each 
dose groups with LTG higher than 10 mg/kg, nor between the 
pre-treated and the post-treated groups (Figure 1).
The effect of LTG on neuron necrosis 
and apoptosis
Nissl’s staining exhibited extensive brain damage in the 
hemisphere that subjected to hypoxic-ischemic injury. The 
regular architecture was destroyed with a marked loss of 
Nissl staining. Multiple necroses with shrinkage of cell body, 
pyknosis of nucleus, loss of Nissl substance, and disappearance 
of nucleolus, were found in the cortex, hippocampus, striatum, 
and thalamus. The impairment was reduced in the treated 
groups with LTG dose higher than 20 mg/kg (Figure 2).
TUNEL positive cells appeared in many regions of the 
ischemic hemisphere including frontal lobe, parietal lobe, 
callosal gyrus, striatum and hippocampus, particularly in 
the pyramidal layer of CA1 region and the granular cell 
layer of dentate gyrus in the hippocampus (Figure 3). Most 
of the TUNEL positive cells had the features of apoptosis 
with typical demilune and apoptotic bodies. The numbers 
of TUNEL positive cells in the cortex and dentate gyrus in 
the ischemic hemisphere were signiﬁ  cantly decreased in 
the LTG-treated groups with doses 10 mg/kg (P  0.01). 
There were signiﬁ  cant differences between each dose groups 
with LTG of 10, 20, and 40 mg/kg. Signiﬁ  cant differences 
were also found between the pre-treated and the post-treated 
groups (P  0.01), but not between the 3 h post-treated and 
the 6 h post-treated groups (Figure 4).
The effect of LTG on NSE level in serum 
and the number of NSE staining neurons
In HI group, NSE staining cells were rarely observed in the 
cerebral cortex and statistic analysis showed a signiﬁ  cant 
decrease in cell count (Figure 5). The NSE level in serum was 
signiﬁ  cantly increased in HI group. The treatment of LTG  20 
mg/kg resulted in a signiﬁ  cant increase of NSE staining cells 
in the cortex and a decrease of NSE level in serum (P  0.01) 
(Figure 6). These changes were more signiﬁ  cant in the pre-
treated group than in the post-treated groups (P  0.01). There 
was no signiﬁ  cant difference between the 3 h post-treated and 
the 6 h post-treated groups.
Discussion
The neuroprotective effect of LTG on HIBD in neonatal 
model has recently been reported (Papazisiset al 2007). 
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Figure 1 Changes in the water content in the cortex of ischemic hemisphere. The asterisks indicate statistically signiﬁ  cant differences vs HI group value (*P  0.01, n = 8 for 
each group). LTG treatment doses and the time points of administration are indicated in horizontal axis.Biologics: Targets & Therapy 2008:2(2) 342
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Further to our preliminary study (Yi et al 2003), the present 
data demonstrate that LTG has a neuroprotective effect on 
HIBD in neonatal rats, shown by reducing the brain edema, 
protecting the neurons from necrosis and apoptosis, and 
inhabiting the leakage of NSE from the neurons. Results from 
the present study provided some evidence of neuroprotection 
of LTG for neonatal HIBD.
The dose-efﬁ  cacy relationship on the neuroprotection of 
LGT has not well deﬁ  ned in previous studies, although there 
is a report from an in vitro experiment (Wang et al 2001). 
In order to study the dose-efﬁ  cacy relationship and to know 
the effective dose of LTG for possible clinical application, 
we tried to quantify HIBD by measuring the water content 
in the cortex, TUNEL, and NSE staining cells in the brain, 
and NSE in serum. Brain edema is one of the basic patho-
logical changes during HI. It is shown that LTG of more 
than 10 mg/kg can signiﬁ  cantly decrease the water content 
in the HI cortex. However, we failed to ﬁ  nd a difference 
between each dose, which might be imputed to the narrow 
range (77.2%–92.4%) of changes in water content, which 
is not sensitive enough to show minor alternations.
A good correlation between dose and efficacy is 
demonstrated in the dose range of 5–40 mg/kg, and the 
effective dose is from 10 mg/kg, shown by the TUNEL cell 
number. The correlation dose range is 10–40 mg/kg and the 
effective dose is from 20 mg/kg, shown by both the NSE 
staining cell number and the NSE concentrations in serum. 
The previous report has demonstrated a good relationship 
between the neurological outcome and serum NSE levels in 
the patients after cardiac arrest (Schoerkhuber et al 1990), 
suggesting that serum NSE levels can reﬂ  ect the degrees 
of brain injury. The increase level of NSE in serum has 
been commonly accepted to be as a maker of the neuronal 
damage. Our results show an elevated NSE level in serum 
with decreased NSE staining in the neurons in neonatal rats 
after HI, conﬁ  rmed that ischemia may cause the leakage of 
cytosolic brain enzymes into the blood and the elevation of 
NSE in serum can reﬂ  ect the degree of brain damage. It is 
clinical signiﬁ  cant because only blood sample can be obtained 
in practice. The effective dose rang of 10–40 mg/kg in the 
present study covered the doses of 10–20 mg/kg that was 
reported previously (Smith and Meldumr 1995; Papazisis1 
et al 2007). LTG of 10–40 mg/kg in rats is equivalent to 
1.6–6.4 mg/kg in human, lower than the dose of 5–15 mg/kg 
for monotherapy in patients with epilepsy. Since LTG could 
be well tolerated within this dose range for partial seizures and 
infantile spasms in infants (Mikati et al 2002), it is reasonable 
to conceive that LTG could be used as a neuroprotective agent 
for HIBD in neonates clinically. The fact that LTG of higher 
doses within the range of 10–40 mg/kg is more effective in 
protecting neuronal damage, shown in the present study, 
suggests that a higher dose within tolerated limit could be 
adopted in practice.
The therapeutic time window is crucial for a 
neuroprotective agent, which is not well deﬁ  ned for LTG. 
Previous studies have selected different time points for 
observation, from 1 h before HI in histotoxic hypoxia model 
(Schulz et al 1995) to 5 h after recovery from cardiac arrest 
in rat (Crumrine et al 1997). The present results show that 
LTG given either before or after HI, may attenuate HIBD 
in neonatal rats, with better effect in the pre-treated group 
and equivalent effect in the groups treated 3 h and 6 h after HI. 
Figure 2 Photomicrographs of Nissl’s staining of the left cerebral cortex. A.  A normal 
imaging from a sham-operated control. B. The regular architecture was destructed in 
the HI cortex. C.   A high power view of the HI cortex, which shows necrosis of the 
cells with shrinkage of the cell body, pyknosis of nucleus, loss of Nissl substance, and 
disappearance of nucleolus. D.   An imaging of the cortex from a subject received LTG 
of 40 mg/kg, 3 h after HI. Scale bar = 250 μm in A, B and D, and 25 μm in C.
Figure 3 Photomicrographs of TUNEL staining of the dentate gyrus.  A. Few TUNEL staining in the dentate gyrus from the sham-operated control. B. Marked TUNEL staining 
in the dentate gyrus in HI group. C. Reduced TUNEL staining in the dentate gyrus from the subject received LTG of 20 mg/kg, 3 h after HI. Scale bar = 250 μm.Biologics: Targets & Therapy 2008:2(2) 343
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Figure 5 Photomicrographs of NSE immunohistochemical staining of the left cerebral cortex. A. Imaging shows the NSE staining neurons in the cortex from the sham-operated control. 
B. Reduced NSE staining in HI group. C. Imaging shows the NSE staining neurons in the cortex from the subject received LTG of 20 mg/kg, 3 h after HI. Scale bar = 50 μm.
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Figure 6 Alternations of the NSE level in serum (n = 8) and the number of NSE staining cells in the cortex (n = 6) in different groups. *Indicates statistically signiﬁ  cant differences 
vs HI group values (P  0.01). NSE level in serum is decreased, whereas the number of NSE staining cells is increased, comparing with HI controls. SIndicates statistically 
signiﬁ  cant differences between LTG treated-groups of 20 mg/kg and 40 mg/kg (P  0.01). TIndicates a statistically signiﬁ  cant difference between the pre-treated and post-treated 
groups (P  0.01).
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Figure 4 Comparison of the number of TUNEL staining cells in the cortex and dentate gyrus in different groups (n = 6). *Indicates statistically signiﬁ  cant differences vs HI group 
values (P  0.01). S Indicates statistically signiﬁ  cant differences between each dose groups (P  0.01). T Indicates statistically signiﬁ  cant difference between the pre-treated and 
post-treated groups (P  0.01).
Extended time points are needed to deﬁ  ne the exact time 
window in further studies.
Clinically, neuroprotective agents may be used either in 
patient known at the risk of hypoxic-ischemic brain injury or 
as post-insult “rescue” therapy. HIBD in neonatal occurs most 
frequently in the antepartum or intrapartum periods during 
which the drug administration is usually difﬁ  cult. Therefore, 
the essential characteristics for a neuroprotective agent in 
prevention and treatment of neonatal HIBD should include: 
First of all, a wide therapeutic time window; secondly, the 
ability to reach peak concentration in the brain rapidly after 
administration; thirdly, it can pass through the placenta 
when it is given during antepartum or intrapartum periods. 
The present study has shown that LTG has a therapeutic 
time window of at least 6 h after hypoxic-ischemia. It is 
demonstrated that LTG can be detected in the CSF 10 min 
after intraperitoneal administration and the penetration half-
time into brain extracellular ﬂ  uid is 0.51 ± 0.11 h (Walker 
et al 2000). It has been reported that the maternal plasma 
LTG concentration at delivery is similar to that from the 
umbilical cord, and the plasma concentration in newborn 
declined slowly after then (Ohman et al 2000; Mikati 
et al 2002). Together, these data suggest that LTG has the 
potential for use as a neuroprotective agent in acute HI in 
neonates, as well as in pregnant women known at the risk 
of perinatal asphyxia.Biologics: Targets & Therapy 2008:2(2) 344
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In summary, the present results demonstrated that 
LTG of tolerable doses initiated either before or after HI 
can attenuate the brain damage in P7 rats, suggesting the 
potential for clinical use in prevention and treatment of 
HIBD.
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